high visibl
color ingenio rx follow-up call management came away
better understand account treatment ingenio rx within antm
addit line item shown revis model figur expect
clariti pbm mechan busi strategi antm analyst day
core health plan busi upshot sg
assumpt rel unchang relat new pbm
oper specif howev previou model antm
slightli optimist side estim vs guid correctli assum
would see cost trend improv medicaid busi management cite
also call normal margin individu busi
 exchang strong growth medicar advantag offset factor
led flat y-o-i guidanc specif exchang seem
margin may increas low doubl digit may
revert back higher end mid singl digit howev would still
compani sustain target margin rate overal compani
rais ep given ep bridg provid note
earlier today combin detail guidanc metric figur rais
ep upon creat similar ep bridg see
figur arriv new ep estim
consist state belief face low execut risk captur
bln expect pbm save elimin esrx vendor contract today
news reinforc notion immedi ep boost even
mid-year transit mani part pbm busi fairli high visibl
better-than-industry-averag ep growth next coupl year combin
addit near-term potenti catalyst carolina medicaid rfp
reiter ow rate new pt base
price-to-earnings higher ep view
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
overweight price target
base price-to-earnings ep compani
set stage acceler ep growth
bn pbm save unlock follow
conclus express script vendor contract
upsid case reflect increas earn visibl
new pbm contract higher expect
downsid case reflect risk associ
increas cost trend aggress commerci price
lower expect medicar growth lower
visibl earn new pbm contract
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
anthem ep bridg
pbm benefit hif ep baselin ep growth high end target ep impli ep pbm dilut share outstand after-tax pbm benefit tax pre-tax pbm benefit ep ep hif pbm adjust ep ep pbm full run-rat ep run-rat ep pre-tax pbm benefit margin tax after-tax pbm benefit dilut share outstand pbm full run-rat ep barclay
 earn guidanceoper revenueapproxim bnpremium bn bnbenefit expens /- bpscost product bn bnsg /- bpsoper gaingreat bnnet invest bninterest mnamort mneffect tax epsgreat epsgreat mnoper flowgreat bnshare bilcost /- bpsmembership insur medic membership benefitback-end weightedseasonalityslighti half earn barclay
inc oper revenu revenueactualactualactualprojectedprojectedprojectedcommerci specialti oper changecommerci specialti oper gain/losscommerci specialti oper margincommerci specialti nm nm nm nm nm total oper changecommerci specialti oper barclay
inc annual incom statement mil ep ep compon oper invest oper invest medic loss expens ex one-tim oper addback expens exclud oper incom total oper rate minor interest check fulli dilut share barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
procedur pleas
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
